期刊
EXPERT REVIEW OF ANTICANCER THERAPY
卷 7, 期 12, 页码 1763-1771出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737140.7.12.1763
关键词
breast cancer; cardiotoxicity; HER2; trastuzumab
类别
The monoclonal antibody against HER2, trastuzumab (Herceptin (R)), has become an important player in the treatment of patients with HER2-positive breast cancer. Both in the metastatic and adjuvant setting, the addition of trastuzumab to other systemic treatments has led to a striking increase in tumor response and survival. The downside with the use of this agent, however, is its inherent cardiotoxicity, which is particularly common when anthracyclines are used concurrently. This review will focus on all aspects of the cardiac side-effects of trastuzumab, ranging from epidemiology and pathophysiology to cardiac monitoring, and treatment and prevention.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据